ArticleTranslational andrology and urology2025
Endoscopic buccal urethroplasty for membranous stricture disease.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optilume Drug-Coated Balloon Dilation for Male Sphincteric (Membranous) Urethral Strictures: 53 Consecutive Cases.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous urethral strictures pose a challenging problem for reconstructive urologists given the difficult location and the impact on continence. Our study aims to expand on the surgical technique, outcomes, and complications of endoscopic buccal mucosal urethroplasty (EBMGU) in the treatment of membranous stricture disease. A single institution retrospective review of patients treated with EBMGU for management of membranous stricture disease between February 2022 and December 2024 was conducted. Patients with obliterative strictures and radiation were also included. Data collected included patient demographics, prior treatments, uroflow, post void residual volumes, stricture characteristics, intraoperative details, and complications. Patients with at least a 4-month follow-up cystoscopy were included. Surgical success was defined as the ability to pass a 17-Fr cystoscope into the bladder at the time of 4-month follow-up. Twenty-eight men are included in this study. Median age was 71 years (range, 46-85 years), and median follow-up was 8 months (range, 4-27 months). Twenty-four (85%) had prior radiation, and 4 had a history of pelvic fracture urethral injury (PFUI). Five (17%) patients had an obliterative stricture disease, 26 (93%) patients had at least one prior intervention, 23 (82%) were patent on 4-month cystoscopy, and these patients had a history of radiation. All patients with a history of PFUI were patent on a 4-month cystoscopy. Sixteen (57%) have gone on to receive an artificial urinary sphincter (AUS), 3 (10%) patients required cystectomy with urinary diversion. One for refractory hematuria due to radiation cystitis, one for refractory symptomatic bladder neck necrosis with sloughing, and one for delayed urosymphyseal fistula in the setting of extensive radionecrosis of the bladder neck. EBMGU is an effective option for management of membranous stricture disease in radiated patients in the short term. Four-month success rates were 82%. More than half of the patients went on to successful AUS placement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.